Loading…
Loading…
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for RAT.L and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for RAT.L and 80,000+ other tickers.
See exactly how RAT.L's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for RAT.L and 80,000+ other tickers.
Rathbones Group Plc specializes in providing personalized investment and wealth management services through its subsidiaries. These services are extended to a diverse clientele, including private individuals, charitable organizations, trusts, and professional associates, primarily within the United Kingdom and Jersey. The company's operations are divided into two main divisions: Investment Management and Funds. Its comprehensive offerings include the oversight of discretionary investment portfolios, administration of unit trusts, financial planning and advisory support, customized managed…
RBC Capital Markets has trimmed its price target for Rathbones Group PLC (LSE:RAT, OTC:RTBBF) to 1,950 pence from 2,400 pence, reflecting a surprise...
Shares in Rathbones Group PLC (LSE:RAT, OTC:RTBBF) tumbled 16.5% to 1,630p on Tuesday after the wealth manager flagged a regulatory review that found...
BSF Enterprise PLC (LSE:BSFA, OTC:BSFAF) said its T-Rex Leather handbag project had successfully validated the structural performance of its advanced tissue...
Optima Health PLC (AIM:OPT, OTC:OHLTF, FRA:J3N) said full-year revenue rose around 15% to approximately £121 million for the year ended 31 March 2026, in...
Panmure Liberum lifts its target price from 2100p to 2600p, arguing the market is still pricing in the old Rathbones, not the one Jonathan Sorrell intends...